Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,290 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Peptide nucleic acid-locked nucleic acid polymerase chain reaction clamp-based detection test for gefitinib-refractory T790M epidermal growth factor receptor mutation.
Miyazawa H, Tanaka T, Nagai Y, Matsuoka M; Huqun; Sutani A, Udagawa K, Zhang J, Hirama T, Murayama Y, Koyama N, Ikebuchi K, Nagata M, Kanazawa M, Nukiwa T, Takenoshita S, Kobayashi K, Hagiwara K. Miyazawa H, et al. Among authors: murayama y. Cancer Sci. 2008 Mar;99(3):595-600. doi: 10.1111/j.1349-7006.2007.00706.x. Cancer Sci. 2008. PMID: 18271876 Free PMC article.
Reliability of the peptide nucleic acid-locked nucleic acid polymerase chain reaction clamp-based test for epidermal growth factor receptor mutations integrated into the clinical practice for non-small cell lung cancers.
Tanaka T, Nagai Y, Miyazawa H, Koyama N, Matsuoka S, Sutani A, Huqun, Udagawa K, Murayama Y, Nagata M, Shimizu Y, Ikebuchi K, Kanazawa M, Kobayashi K, Hagiwara K. Tanaka T, et al. Among authors: murayama y. Cancer Sci. 2007 Feb;98(2):246-52. doi: 10.1111/j.1349-7006.2006.00377.x. Cancer Sci. 2007. PMID: 17233841 Free PMC article.
Gefitinib for non-small-cell lung cancer patients with epidermal growth factor receptor gene mutations screened by peptide nucleic acid-locked nucleic acid PCR clamp.
Sutani A, Nagai Y, Udagawa K, Uchida Y, Koyama N, Murayama Y, Tanaka T, Miyazawa H, Nagata M, Kanazawa M, Hagiwara K, Kobayashi K. Sutani A, et al. Among authors: murayama y. Br J Cancer. 2006 Dec 4;95(11):1483-9. doi: 10.1038/sj.bjc.6603466. Epub 2006 Nov 14. Br J Cancer. 2006. PMID: 17106442 Free PMC article. Clinical Trial.
Re-challenge of afatinib after 1st generation EGFR-TKI failure in patients with previously treated non-small cell lung cancer harboring EGFR mutation.
Yamaguchi O, Kaira K, Mouri A, Shiono A, Hashimoto K, Miura Y, Nishihara F, Murayama Y, Kobayashi K, Kagamu H. Yamaguchi O, et al. Among authors: murayama y. Cancer Chemother Pharmacol. 2019 May;83(5):817-825. doi: 10.1007/s00280-019-03790-w. Epub 2019 Feb 13. Cancer Chemother Pharmacol. 2019. PMID: 30758646
Severe hepatotoxicity due to osimertinib after nivolumab therapy in patients with non-small cell lung cancer harboring EGFR mutation.
Yamaguchi O, Kaira K, Kawasaki T, Mouri A, Hashimoto K, Shiono A, Shinomiya S, Miura Y, Nishihara F, Murayama Y, Kobayashi K, Mochida S, Kagamu H. Yamaguchi O, et al. Among authors: murayama y. Thorac Cancer. 2020 Apr;11(4):1045-1051. doi: 10.1111/1759-7714.13363. Epub 2020 Feb 18. Thorac Cancer. 2020. PMID: 32068351 Free PMC article. Clinical Trial.
[Hange-Shashin-to for preventing diarrhea during afatinib therapy].
Yamaguchi O, Kawashima A, Shiono A, Maeno Y, Ishikawa R, Masumoto A, Utsugi H, Daito H, Okano T, Murayama Y, Kobayashi K. Yamaguchi O, et al. Among authors: murayama y. Gan To Kagaku Ryoho. 2015 May;42(5):581-3. Gan To Kagaku Ryoho. 2015. PMID: 25981651 Japanese.
Clinical significance of primary prophylactic pegylated-granulocyte-colony stimulating factor after the administration of ramucirumab plus docetaxel in patients with previously treated non-small cell lung cancer.
Mouri A, Kaira K, Shiono A, Yamaguchi O, Murayama Y, Kobayashi K, Kagamu H. Mouri A, et al. Among authors: murayama y. Thorac Cancer. 2019 Apr;10(4):1005-1008. doi: 10.1111/1759-7714.13022. Epub 2019 Mar 11. Thorac Cancer. 2019. PMID: 30859745 Free PMC article.
CD4+ T-cell Immunity in the Peripheral Blood Correlates with Response to Anti-PD-1 Therapy.
Kagamu H, Kitano S, Yamaguchi O, Yoshimura K, Horimoto K, Kitazawa M, Fukui K, Shiono A, Mouri A, Nishihara F, Miura Y, Hashimoto K, Murayama Y, Kaira K, Kobayashi K. Kagamu H, et al. Among authors: murayama y. Cancer Immunol Res. 2020 Mar;8(3):334-344. doi: 10.1158/2326-6066.CIR-19-0574. Epub 2019 Dec 23. Cancer Immunol Res. 2020. PMID: 31871122
1,290 results